Immutep shares more than double after FDA grants orphan drug designation for sarcoma candidate

Immutep Limited (IMMP) is up 107.6% today. Here is some analysis on what might have caused this price movement.

Analysis: The surge appears tied to Immutep’s announcement that the FDA granted Orphan Drug Designation (ODD) to eftilagimod alfa (efti) for soft tissue sarcoma, a regulatory milestone that can improve a drug program’s economics and visibility. Traders also seem to be re-rating the asset based on the company’s cited Phase II data in resectable soft tissue sarcoma.

Details:

Immutep said the FDA granted ODD for efti for the treatment of soft tissue sarcoma on April 15, 2026.

The company noted ODD benefits can include regulatory support, certain tax credits and fee exemptions, and potential seven-year U.S. market exclusivity if the drug is ultimately approved.

Immutep highlighted investigator-initiated Phase II EFTISARC-NEO results in 38 evaluable patients, reporting a median tumour hyalinization/fibrosis of 51.5%, above the trial’s pre-specified 35% target.

Management framed the designation as a potential step toward a late-stage study in this setting while it continues a broader review after stopping its Phase III TACTI-004 study.

Sources:

Immutep, StockTitan, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

EARLY ACCESS

Receive IMMP Data Alerts

Real-time alerts on filings, insider trades, and market signals — before everyone else.

Get Alerts →

$IMMP Hedge Fund Activity

We have seen 11 institutional investors add shares of $IMMP stock to their portfolio, and 20 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

BLACKROCK, INC. added 243,097 shares (+41.9%) to their portfolio in Q4 2025, for an estimated $695,257
SENDER CO & PARTNERS, INC. removed 215,861 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $617,362
MORGAN STANLEY removed 159,394 shares (-96.0%) from their portfolio in Q4 2025, for an estimated $455,866
TWO SIGMA INVESTMENTS, LP added 94,595 shares (+inf%) to their portfolio in Q4 2025, for an estimated $270,541
MILLENNIUM MANAGEMENT LLC added 57,454 shares (+116.5%) to their portfolio in Q4 2025, for an estimated $164,318
UBS GROUP AG added 45,324 shares (+180.6%) to their portfolio in Q4 2025, for an estimated $129,626
CITADEL ADVISORS LLC removed 44,072 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $126,045

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.

$IMMP Price Targets

Multiple analysts have issued price targets for $IMMP recently. We have seen 2 analysts offer price targets for $IMMP in the last 6 months, with a median target of $5.5.

Here are some recent targets:

Joel Beatty from Baird set a target price of $1.0 on 03/13/2026
Reni J. Benjamin from Citizens set a target price of $10.0 on 02/23/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.